Roberta Loveikyte
Leiden, ZH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Letter: External Validation of Hepcidin Thresholds for Predicting Response to Iron Therapy in Active Inflammatory Bowel Disease. Authors' Reply.
Journal: Alimentary pharmacology & therapeutics
Published: August 05, 2026
Clinical Trial: Predicting Response to Iron Therapy in Patients With Active Inflammatory Bowel Disease Using Hepcidin and Functional Iron Indices: A Multicentre Randomised Trial.
Journal: Alimentary pharmacology & therapeutics
Published: February 18, 2026
Increased remodeling of type XXII collagen is associated with an inflammatory phenotype in Crohn's disease.
Journal: Scientific reports
Published: January 16, 2026
Multimodal Lifestyle Intervention Improves Fatigue in Quiescent Inflammatory Bowel Disease: A Controlled Study.
Journal: Crohn's & colitis 360
Published: August 04, 2024
Predicting response to iron supplementation in patients with active inflammatory bowel disease (PRIme): a randomised trial protocol.
Journal: BMJ open
Published: January 31, 2024
The effect of iron therapy on oxidative stress and intestinal microbiota in inflammatory bowel diseases: A review on the conundrum.
Journal: Redox biology
Published: October 22, 2023
Anemia and Iron Deficiency in Outpatients with Inflammatory Bowel Disease: Ubiquitous Yet Suboptimally Managed.
Journal: Journal of clinical medicine
Published: October 14, 2022
Hepcidin and Iron Status in Patients With Inflammatory Bowel Disease Undergoing Induction Therapy With Vedolizumab or Infliximab.
Journal: Inflammatory bowel diseases
Published: September 06, 2022
Serological Biomarkers of Extracellular Matrix Turnover and Neutrophil Activity Are Associated with Long-Term Use of Vedolizumab in Patients with Crohn's Disease.
Journal: International journal of molecular sciences
Published: June 27, 2022
Serological Biomarkers of Intestinal Collagen Turnover Identify Early Response to Infliximab Therapy in Patients With Crohn's Disease.
Journal: Frontiers in medicine
Published: May 01, 2022
Serological biomarkers of type I, III and IV collagen turnover are associated with the presence and future progression of stricturing and penetrating Crohn's disease.
Journal: Alimentary pharmacology & therapeutics
Published: February 04, 2022
Showing 1-12 of 12
Last Updated: 09/26/2026